Objective: To evaluate the efficacy & safety of blinatumomab (Blincyto®) in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) dosed either stepwise (9-28-112 mcg/day) with weekly dose increases or as a single continuous infusion (112 mcg/day). Both groups used dexamethasone for prophylaxis.
Statistics: Time-to-event variables (Kaplan-Meier method). ORR for evaluable patients (received study drug at target dose for at least 7 days or discontinued due to disease progression) Progressive disease---10/21 (47.6%) • Among the 4 patients not included, 1 remained stable, 3 were not evaluated • Median DOR à 11.6 months (95% CI 0.9 to not estimable)
DOR not measurable • ORR relapsed disease at baseline à 6/9 (67%) DOR à 8.7 months (range 0.7-17.5 months) • Median PFS à 3.7 months (95% CI 1.4-7.7) ongoing (longest PFS 20.1 months) • Median overall survival 5.0 months (95% CI 2.3 to not estimable); Median follow up 11.7 months at time of analysis •patients prior autologous HSCT; Δ, bulky disease (>7.5 cm); o, transformed disease baseline. PD, progressive disease; SD, stable
Author's Conclusions & Comments:
• Results corroborate phase I trial results: 6/11 (55%) patients with r/r DLBCL responded with 4 CR (36%) o For patients with r/r Non-Hodgkin's Lymphoma, maximum tolerated dose (MTD) 60 mcg/m 2 given in two-step dosing of 5 mcg/m2 on days 1-7; 15 mcg/m 2 on days 8-14; then 60 mcg/m2; median response duration 404 days (95% CI: 201-1129) (ME Goebleler, 2016) • At least one week at target dose of 112 mcg/day needed for efficacy (referenced Phase I study, no reference) o 39% of patients in step-wise dosing discontinued because of early tumor progression àmore rapid dose escalation may have been beneficial
• 3 patients with PR at week 11 later achieved a CR as measured by PET (Used Cheson criteria, 1 st time to assess) o Evaluation time scale may need to be expanded • Blinatumomab efficacy compared to other published r/r DLBCL drugs studied o Pinatuzumab bedotin (ORR 39%), Y-ibrutumomab tiuxetan (ORR 53%), lenalidomide (ORR 35%), nivolumab (ORR 36%), inotuzumab ozogamicin (ORR 15%), ibrutinib (ORR 225), buparlisib (ORR 12%) • Patients in this study were refractory and had short time since last treatment (1.5 months)
o Response rate was lower (19%) than in patients with later relapse (67%) • All patients with disease progression leading to discontinuation were refractory (Figure 1) o Phase I studies showed neurologic events were dose limiting with a maximum tolerated dose of 60 mcg/day continuous infusion (4 to 8 weeks).
Phase II Results (December 2015): BLAST trial Abstracts
• 116 patients with B-cell precursor ALL & persistent or recurrent minimal residual disease (MRD)
Phase III results (Feb 2016); http://www.amgen.com/media/news-releases/2016/02/phase-3-study-of-blincytoblinatumomab-met-primary-endpoint-of-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblasticleukemia/ Interim analysis showed the primary endpoint of overall survival was met in the TOWER phase III, randomized, openlabel study versus standard of care in adults with Philadelphia chromosome negative r/r B-cell precursor acute lymphoblastic lymphoma. Dosing: continuous IV infusion over 6 weeks with 4 weeks of blinatumomab followed by 2 week treatment free interval. First induction cycle: initial dose 9 mcg/day x 7days then 28 mcg/day starting on day 8 through day 29 (week 4). All subsequent cycles (starting with second induction cycle through consolidation) will be at 28 mcg/day for all 4 weeks.
Epidemiology:
• •DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation fraction (picture 2). Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a). The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. (See 'Pathology' above.)
•The diagnosis of DLBCL is best made based by excisional tissue biopsy, most commonly a lymph node. The diagnosis is based on morphology and immunophenotyping, which is essential to make the diagnosis. (See 'Diagnosis' above.)
•The differential diagnosis of DLBCL includes other large cell malignancies, such as carcinoma, melanoma, and other types of lymphoma (table 2) . (See 'Differential diagnosis'above.)
•It is increasingly appreciated that the diagnostic category of "DLBCL" is quite heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized that are sufficiently distinct to be considered separate diagnostic categories:
•T cell rich large B cell lymphoma (see 'T cell histocyte rich large B cell lymphoma' above)
•Primary mediastinal large B cell lymphoma (see 'Primary mediastinal large B cell lymphoma' above)
•Intravascular lymphoma (see 'Intravascular large B cell lymphoma' above)
•Lymphomatoid granulomatosis and EBV-positive DLBCL of the elderly (see 'Lymphomatoid granulomatosis' above and 'EBV-positive DLBCL of the elderly' above) neutrophils 2-5 days, eosinophils 7-12 days, basophils 12-15 days, monocytes 2-5 days, lymphocytes ½ to 1 day, megakaryocytes platelets 9-12 days Current Treatment: Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Tilly et al. 2015 Annals of Oncology 26 (S5): 116-125 Table 3 . Recommended treatment strategies in diffuse large B-cell lymphoma
